VCANBIO(SH:600645) Zhong Zheng Wang·2025-10-31 11:31Core Insights - Zhongyuan Xiehe has received approval from the National Medical Products Administration for its VUM02 injection to conduct Phase IIa clinical trials for treating post-pneumonia progressive pulmonary fibrosis [1] - The company has a total of 10 indications approved for IND for VUM02, including severe COVID-19 and pneumonia, with some already in Phase II/III trials [1][2] Clinical Research Progress - VUM02 injection has completed all subject dosing in Phase I trials for idiopathic pulmonary fibrosis (IPF) and is currently organizing clinical safety and efficacy data [1] - The company’s equity stake in Beijing Sanyouli and Ze Biotechnology has led to the completion of subject enrollment for Phase II clinical trials of a human dental pulp mesenchymal stem cell injection [1] Product Development - VUM02 and VUM03 injections have collectively received approval for 11 INDs, reinforcing the company's competitive edge in the stem cell field and serving as a foundation for sustainable development [2]